Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lasergen is a topical facial cream developed by Endor Nanotechnology and marketed by Endor Technologies as a nanoparticle-based regenerative skin care product for dermatologic and cosmetic use. It is described as an anti-aging and post-procedure restorative cream intended to help repair skin damage associated with aging and to improve the appearance of skin after clinical procedures such as ablative laser treatments, with claimed benefits on firmness, volume, hydration, post-inflammatory hyperpigmentation, acne scars, wrinkles, and sagging. The product is presented as using the company's hyaluronic-acid-based nanotechnology platform, including a claimed bioactive or activated hyaluronan component, but no discrete molecular target or well-defined pharmacologic mechanism has been publicly disclosed. It appears to be a marketed dermocosmetic product rather than a conventional prescription pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lasergen.